INCPF Stock Chart & Stats
$1.55
--
Market closed
$1.55
--
Day’s Range― - ―
52-Week Range$1.55 - $3.26
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$2.72B
Enterprise Value$13.85K
Total Cash (Recent Filing)$8.37B
Total Debt (Recent Filing)$2.23B
Price to Earnings (P/E)23.5
Beta0.20
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.52
Shares Outstanding1,496,284,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)2.52
Price to Sales (P/S)8.47
P/FCF Ratio148.84
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$2.53Price Target Upside62.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.03
Revenue Forecast (FY)$329.58M
Bulls Say, Bears Say
Bulls Say
Revenue And Profitability InflectionThe sharp revenue increase and return to profit indicate stronger commercial execution and operating leverage. If drug sales growth remains durable, the improved earnings base can support reinvestment, strengthen the company’s competitive position, and reduce reliance on external funding.
Liquidity And R&D CapacityA substantial cash balance gives InnoCare capacity to fund clinical development, regulatory submissions, and commercialization without immediately depending on partnerships or capital markets. Continued R&D investment also supports pipeline renewal and the potential for additional products over time.
Commercial Footprint And Pipeline ProgressAn established commercial infrastructure provides a foundation for expanding approved medicines and launching future products. Combined with broad late-stage development activity, this footprint can improve the company’s ability to convert regulatory milestones into recurring pharmaceutical revenue.
Bears Say
Weak Cash ConversionCash generation has improved, but the large gap between accounting profit and operating cash flow means earnings quality is not yet fully established. Persistently weak conversion could constrain internal funding for trials and commercialization, especially if profitability softens.
Orelabrutinib Revenue ConcentrationDependence on one principal commercial product increases exposure to product-specific competition, regulatory developments, and changes in prescribing or reimbursement. Until newer medicines contribute materially, revenue growth and cash generation remain less diversified.
Clinical Timing And Execution RiskLong enrollment periods postpone potential approvals and commercial contributions from important programs. Delays or execution problems could extend the period before pipeline assets diversify revenue, while increasing development costs and leaving near-term results more dependent on existing products.
InnoCare Pharma Ltd. News
INCPF FAQ
What was InnoCare Pharma Ltd.’s price range in the past 12 months?
InnoCare Pharma Ltd. lowest stock price was $1.55 and its highest was $3.26 in the past 12 months.
What is InnoCare Pharma Ltd.’s market cap?
InnoCare Pharma Ltd.’s market cap is $2.72B.
When is InnoCare Pharma Ltd.’s upcoming earnings report date?
InnoCare Pharma Ltd.’s upcoming earnings report date is Nov 16, 2026 which is in 49 days.
How were InnoCare Pharma Ltd.’s earnings last quarter?
InnoCare Pharma Ltd. released its earnings results on Aug 24, 2026. The company reported $0.012 earnings per share for the quarter, beating the consensus estimate of $0.01 by $0.001.
Is InnoCare Pharma Ltd. overvalued?
According to Wall Street analysts InnoCare Pharma Ltd.’s price is currently Undervalued.
Does InnoCare Pharma Ltd. pay dividends?
InnoCare Pharma Ltd. does not currently pay dividends.
What is InnoCare Pharma Ltd.’s EPS estimate?
InnoCare Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does InnoCare Pharma Ltd. have?
InnoCare Pharma Ltd. has 1,496,284,200 shares outstanding.
What happened to InnoCare Pharma Ltd.’s price movement after its last earnings report?
InnoCare Pharma Ltd. reported an EPS of $0.012 in its last earnings report, beating expectations of $0.01. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of InnoCare Pharma Ltd.?
Currently, no hedge funds are holding shares in INCPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
InnoCare Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.53 (62.99% Upside)
$2.53 (62.99% Upside)
Blogger Sentiment
Bullish
INCPF Sentiment 100%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-19.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
26.39%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
InnoCare Pharma Ltd.
InnoCare Pharma Limited, a biopharmaceutical enterprise, specializes in the discovery, development, and commercialization of therapeutic agents for oncological and autoimmune disorders. Its lead product, Orelabrutinib, a BTK inhibitor, addresses a wide range of conditions, including various forms of relapsed and/or refractory (r/r) lymphomas (such as chronic lymphocytic leukemia, mantle cell lymphoma, Waldenstrom's macroglobulinemia, marginal zone lymphoma, specific diffuse large B-cell lymphomas, and central nervous system lymphoma). It also targets systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder, sometimes utilized in combination therapies. The company's robust pipeline features several key candidates: ICP-192, a pan-FGFR inhibitor in Phase I/II clinical trials for solid tumors, notably cholangiocarcinoma and head and neck cancer; ICP-723, a pan-TRK inhibitor undergoing Phase I evaluation for cancers positive for neurotrophic tyrosine receptor kinase fusion; ICP-332, a novel tyrosine kinase 2 inhibitor in Phase I for autoimmune diseases; and ICP-B02, a bispecific antibody developed for lymphoma treatment. Furthermore, InnoCare is advancing ICP-189, ICP-915, and ICP-B03 for solid tumors; ICP-033 for liver cancer, renal cell carcinoma, colorectal cancer, and other solid malignancies; ICP-488 for autoimmune conditions; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody targeting various cancers; ICP-248 for hematological indications; and ICP-490 for both hematology and autoimmune disorders. In addition, the firm offers ICP-B04 (Tafasitamab) for the treatment of DLBCL and other hematological conditions. InnoCare Pharma Limited was established in 2015 and maintains its headquarters in Beijing, China.
INCPF Stock 12 Month Forecast
Average Price Target
$2.53
▲(62.99% Upside)
Technical Analysis
Zai Lab Ltd
―
CARsgen Therapeutics Holdings Ltd.
―
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
―
CStone Pharmaceuticals
―
Ascentage Pharma Group International
―
Ownership Overview
―
Insiders
3.11% Mutual Funds
― Other Institutional Investors
93.70% Public Companies and
Individual Investors